In summary, in adults dealing with overweight or obesity (with at least one weight-related comorbidity), semaglutide treatment resulted in significant and sustained weight loss over the 104-week period compared to placebo
The broader benefits beyond glucose control are increasingly recognised in clinical decision-making, though prescribing decisions should be individualised based on patient characteristics, comorbidities, and treatment goals
Weekly measurements Body weight (understand the creatine water weight caveat): Weigh yourself under the same conditions daily, same time, same clothing (or none), after using the bathroom
The right treatment depends on medical history, safety, FDA approval status, access, tolerance, side effects, muscle-preservation needs, metabolic risk, and long-term planning